Taysha Gene Therapies Stock Investor Sentiment

TSHA Stock  USD 1.93  0.05  2.66%   
About 56% of all Taysha Gene's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Taysha Gene Therapies suggests that some traders are interested. The current market sentiment, together with Taysha Gene's historical and current headlines, can help investors time the market. In addition, many technical investors use Taysha Gene Therapies stock news signals to limit their universe of possible portfolio assets.
  

Taysha Gene Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Taysha Gene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at news.google.com         
Taysha Gene Therapies, Inc. Sees Large Increase in Short Interest - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Taysha Gene Therapies, Inc. Short Interest Update - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Taysha Gene Therapies Earns Buy Rating from Needham Company LLC - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Research Analysts Issue Forecasts for Taysha Gene Therapies, Inc.s FY2024 Earnings - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Goodwin Represents the Underwriters For Taysha Gene Therapies 75 Million Public Offering - Goodwin P...
Google News at Macroaxis
over six months ago at globenewswire.com         
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635
Yahoo News
over six months ago at simplywall.st         
Insider Spends US3.0m Buying More Shares In Taysha Gene Therapies
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Taysha Shares Positive Rett Results in Bid to Move Past Roadblocks - BioSpace
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Insider Buyers At Taysha Gene Therapies Sitting On US24m Profit
Yahoo News
over six months ago at simplywall.st         
More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.s Shares After Tumbling 3...
Simply Wall St News at Macroaxis
over six months ago at simplywall.st         
Acquisition by Manning Paul B of 1333333 shares of Taysha Gene at 2.25 subject to Rule 16b-3
Simply Wall St News at Macroaxis
over six months ago at seekingalpha.com         
Biggest stock movers today RIVN, FDX, TSHA
seekingalpha News
over six months ago at globenewswire.com         
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - S...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Taysha Gene that are available to investors today. That information is available publicly through Taysha media outlets and privately through word of mouth or via Taysha internal channels. However, regardless of the origin, that massive amount of Taysha data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Taysha Gene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Taysha Gene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Taysha Gene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Taysha Gene alpha.

Taysha Gene Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Nagendran Sukumar of 790093 shares of Taysha Gene subject to Rule 16b-3
10/18/2024
2
Piper Sandler stays bullish on Taysha Gene shares, maintains Overweight rating
11/12/2024
3
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/2024
4
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursdays Pre-Market Session
11/14/2024
5
Taysha Gene Therapies Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags
11/15/2024
6
Taysha Gene Therapies Trading Up 13.8 percent - Heres What Happened - MarketBeat
11/22/2024
7
Taysha Gene Therapies Shares Gap Down Heres Why
12/04/2024
8
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635
12/06/2024
9
Acquisition by Alam Kamran of 149900 shares of Taysha Gene at 1.18 subject to Rule 16b-3
12/13/2024
10
Acquisition by Alam Kamran of 431000 shares of Taysha Gene at 1.85 subject to Rule 16b-3
01/02/2025
11
Needham Company LLC Reiterates Buy Rating for Taysha Gene Therapies
01/08/2025

Complementary Tools for Taysha Stock analysis

When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments